地舒单抗治疗马来西亚绝经后骨质疏松症的成本效益
从马来西亚医疗服务提供者视角,采用Markov模型比较地舒单抗与阿仑膦酸钠及不治疗在50至80岁无骨折史绝经后骨质疏松女性中的成本效益,结果显示地舒单抗在60岁及以上女性中具成本效益,ICER随年龄增长而降低。
要点
- 地舒单抗在60岁及以上绝经后骨质疏松女性中具成本效益。
- 地舒单抗对比阿仑膦酸钠的ICER从60岁的MYR 16,955/QALY降至80岁的MYR 4,380/QALY。
- 在成本效益阈值下,地舒单抗具有成本效益的概率为72.8%至92.7%。
核心结论
- 从马来西亚医疗服务提供者视角,地舒单抗似乎是60岁以上绝经后骨质疏松女性的具成本效益的治疗选择。
研究设计与样本
- 采用经验证的Markov模型,在50至80岁无骨折史的假设绝经后骨质疏松女性队列中,从马来西亚医疗服务提供者视角进行10年时间跨度的成本效益分析。
- 模型参数包括转移概率和成本基于马来西亚来源,疗效数据来自网络Meta分析,结局以每获得一个质量调整生命年(QALY)的增量成本表示。
- 成本效益阈值设定为每QALY MYR 21,438(USD 5175)。
主要发现
- 地舒单抗在60岁及以上绝经后骨质疏松女性中被发现是具成本效益的选择。
- 地舒单抗对比阿仑膦酸钠的增量成本效果比(ICER)从60岁的每QALY MYR 16,955(USD 4093)至80岁的每QALY MYR 4,380(USD 1057)。
- 地舒单抗的成本效益随年龄增长单调改善。
- 在成本效益阈值下,地舒单抗具有成本效益的概率为72.8%至92.7%。
- 敏感性分析显示结果在所有参数变化下稳健,地舒单抗的年成本是最敏感的参数。
关键数值与推荐
- 成本效益阈值:每QALY MYR 21,438(USD 5175)。
- 地舒单抗对比阿仑膦酸钠的ICER:60岁每QALY MYR 16,955(USD 4093),80岁每QALY MYR 4,380(USD 1057)。
- 地舒单抗具有成本效益的概率:72.8%至92.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: From the perspective of Malaysian health care providers, denosumab was cost-effective in the treatment of postmenopausal osteoporosis, with an optimal outcome starting at age 60 years. Our results provide important insights into the value for money of anti-osteoporotic agents that can serve as a reference for other countries with comparable epidemiological data. INTRODUCTION: The study aimed to compare the cost-effectiveness of denosumab with alendronate and no treatment in the management of postmenopausal osteoporosis among the Malaysian population. METHODS: A well-validated Markov model was used to estimate the cost-effectiveness of denosumab in a hypothetical cohort of postmenopausal osteoporotic women between 50 and 80 years old who had no history of fractures. A 10-year time horizon from the perspective of Malaysian health care providers was used in this analysis. The model parameters, including transition probabilities and costs, were based on Malaysian sources. Treatment efficacy data were obtained from a network meta-analysis. The study outcomes were presented as incremental cost per quality-adjusted life-year (QALY) gained. Sensitivity analyses were performed to ensure the robustness of the results. A cost-effectiveness threshold was set at MYR 21,438 (USD 5175) per QALY. RESULTS: Denosumab was found to be a cost-effective option for postmenopausal osteoporotic women aged 60 and older. The incremental cost-effectiveness ratios (ICERs) for denosumab versus alendronate ranged from MYR 16,955 (USD 4093) per QALY at age 60 to MYR 4380 (USD 1057) per QALY at age 80. The cost-effectiveness of denosumab improved monotonically with increasing age. Denosumab was 72.8-92.7% likely to be cost-effective at the cost-effectiveness threshold. Sensitivity analyses demonstrated that the results were robust across all parameter variations, with the annual cost of denosumab being the most sensitive. CONCLUSIONS: From the perspective of the Malaysian health care provider, denosumab appears to be a cost-effective treatment choice for postmenopausal osteoporotic women over 60 years of age.
引用
- Choo YW, Mohd Tahir NA, Mohamed Said MS, et al. Cost-effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in Malaysia. Osteoporos Int. 2022. PMID: 35641572. doi:10.1007/s00198-022-06444-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。